The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial

Baseline low ctDNA levels predict response to targeted therapy, potentially suggesting shared mechanisms between high ctDNA release and resistance to therapy. Both baseline ctDNA levels and on-treatment dynamics are a promising surrogate endpoint for drug development, with clearance of ctDNA being a robust cross-therapy surrogate for outcomes.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2025-10-29
DOI
https://doi.org/10.1158/1078-0432.ccr-24-0651
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial

Javier Pascual, Judith M. Bliss, Alistair Ring, Isaac García-Murillas et al.
Clinical Cancer Research
Cancer Genomics and Diagnostics
article

The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial

Javier Pascual, Judith M. Bliss, Alistair Ring, Isaac García-Murillas, Belinda Kingston, Miguel Gil‐Gil, Iain R. Macpherson, Alex Pearson, Ángel Guerrero‐Zotano, Rebecca Roylance, Rosalind Cutts, Sarah Hrebien, Lucy Kilburn, Nicholas C. Turner, Laura Moretti, Andrew Wardley, Richard D. Baird, Iseult Browne, Miguel Martín
article en

Abstract

Baseline low ctDNA levels predict response to targeted therapy, potentially suggesting shared mechanisms between high ctDNA release and resistance to therapy. Both baseline ctDNA levels and on-treatment dynamics are a promising surrogate endpoint for drug development, with clearance of ctDNA being a robust cross-therapy surrogate for outcomes.

Clinical Cancer ResearchVol. 32(1)
Royal Marsden NHS Foundation Trust (GB), University College London Hospitals NHS Foundation Trust (GB), Institute of Cancer Research (GB), Breast Cancer Now (GB), Cancer Research UK (GB), Hospital General Universitario Gregorio Marañón (ES), Cancer Research UK Cambridge Center (GB), Fundación Instituto Valenciano de Oncología (ES), Institut Català d'Oncologia (ES), Royal Marsden Hospital (GB), The Christie NHS Foundation Trust (GB), UCL Biomedical Research Centre (GB), Cancer Services (US), Hospital Clínico Universitario Virgen de la Victoria (ES), Centro de Investigación Biomédica en Red de Cáncer (ES), GEICAM – Spanish Breast Cancer Group (ES), University College London (GB), University of Glasgow (GB)
Openalex Percentile: Top 62%
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.